Abstract Library

#2730 FOLFIRINEC, A Multi-Center, Randomized, Comparative Phase II Study of FOLFIRINOX vs Platinum-Etoposide as First Line Treatment for Metastatic Neuroendocrine Carcinoma of Gastroenteropancreatic or Unknown Origin, Associated with Molecular Profiling

Introduction: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine carcinoma (NEC) are rare diseases with a poor prognosis. FOLFIRINEC is a multicenter comparative phase II study of mFOLFIRINOX vs platinum-etoposide (PE) as first line treatment for metastatic G3 NEC of GEP or unknown origin.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hadoux J

Authors: Hadoux J, Afchain P, Walter T, Tougeron D, Hautefeuille V,

Keywords: neuroendocrine carcinoma, gastroenteropancreatic, chemotherapy, FOLFIRINOX, RB,

#2222 Biliary Mixed Neuroendocrine-Nonneuroendocrine Neoplasms: A Series of Four Cases with Review of Literature

Introduction: Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs) are rare tumors comprising of both adenocarcinoma and neuroendocrine component, at least 30% of each in the lesion.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Pande P

Authors: Pande P, Desai G, Shah R, Palepu J,

Keywords: minen, biliary mixed neuroendocrine-nonneuroendocrine neoplasms,

#1706 Effectiveness of Chemoterapy in Advanced PanNETs with ki67<55%: Monocentric Experience

Introduction: Pancreatic Neuroendocrine Tumors (panNETs) are neoplasms with heterogeneous clinical behaviour. There is no standard treatment.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Antista M, Cingarlini S, Grego E, Ortolani S, Scarpa A,

Keywords: chemotherapy, neuroendocrine, pan NETs, ki67<55%,